CGBIO to supply NOVOSIS to LifeHealthcare in Australia

CGBIO announced an agreement with LifeHealthcare to supply its rhBMP-2 bone graft product NOVOSIS for the Australian and New Zealand markets, with potential revenue of KRW 200 billion.

“We have an aim to expand biopharmaceutical business in orthopedics and neurosurgery by strong sales of NOVOSIS.”cgbio.co.kr

• 1 source
• cgbio.co.krCGBIO to supply NOVOSIS to LifeHealthcare in Australia rhBMP-2 – CGBIO_ENcgbioOct 12, 2020

Summarized from public sources; check the original articles before acting on it.